Quantitative structure-activity relationship: promising advances in drug discovery platforms
- PMID: 26358617
- DOI: 10.1517/17460441.2015.1083006
Quantitative structure-activity relationship: promising advances in drug discovery platforms
Abstract
Introduction: Quantitative structure-activity relationship (QSAR) modeling is one of the most popular computer-aided tools employed in medicinal chemistry for drug discovery and lead optimization. It is especially powerful in the absence of 3D structures of specific drug targets. QSAR methods have been shown to draw public attention since they were first introduced.
Areas covered: In this review, the authors provide a brief discussion of the basic principles of QSAR, model development and model validation. They also highlight the current applications of QSAR in different fields, particularly in virtual screening, rational drug design and multi-target QSAR. Finally, in view of recent controversies, the authors detail the challenges faced by QSAR modeling and the relevant solutions. The aim of this review is to show how QSAR modeling can be applied in novel drug discovery, design and lead optimization.
Expert opinion: QSAR should intentionally be used as a powerful tool for fragment-based drug design platforms in the field of drug discovery and design. Although there have been an increasing number of experimentally determined protein structures in recent years, a great number of protein structures cannot be easily obtained (i.e., membrane transport proteins and G-protein coupled receptors). Fragment-based drug discovery, such as QSAR, could be applied further and have a significant role in dealing with these problems. Moreover, along with the development of computer software and hardware, it is believed that QSAR will be increasingly important.
Keywords: comparative molecular field analysis; comparative molecular similarity indices analysis; machine learning; quantitative structure–activity relationship; rational design; virtual screening.
Similar articles
-
Latest advances in molecular topology applications for drug discovery.Expert Opin Drug Discov. 2015;10(9):945-57. doi: 10.1517/17460441.2015.1062751. Epub 2015 Jul 2. Expert Opin Drug Discov. 2015. PMID: 26134383 Review.
-
QSAR studies in the discovery of novel type-II diabetic therapies.Expert Opin Drug Discov. 2016;11(2):197-214. doi: 10.1517/17460441.2016.1118046. Epub 2015 Dec 1. Expert Opin Drug Discov. 2016. PMID: 26558613 Review.
-
The advancement of multidimensional QSAR for novel drug discovery - where are we headed?Expert Opin Drug Discov. 2017 Aug;12(8):769-784. doi: 10.1080/17460441.2017.1336157. Epub 2017 Jun 8. Expert Opin Drug Discov. 2017. PMID: 28562095 Review.
-
QSAR and 3D-QSAR studies applied to compounds with anticonvulsant activity.Expert Opin Drug Discov. 2015 Jan;10(1):37-51. doi: 10.1517/17460441.2015.968123. Epub 2014 Oct 9. Expert Opin Drug Discov. 2015. PMID: 25297377 Review.
-
Role of computer-aided drug design in modern drug discovery.Arch Pharm Res. 2015 Sep;38(9):1686-701. doi: 10.1007/s12272-015-0640-5. Epub 2015 Jul 25. Arch Pharm Res. 2015. PMID: 26208641 Review.
Cited by
-
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.Comput Biol Med. 2021 Jun;133:104359. doi: 10.1016/j.compbiomed.2021.104359. Epub 2021 Mar 30. Comput Biol Med. 2021. PMID: 33845270 Free PMC article.
-
Learning the structure-activity relationship (SAR) of the Wittig reaction from genetically-encoded substrates.Chem Sci. 2021 Oct 21;12(42):14301-14308. doi: 10.1039/d1sc04146k. eCollection 2021 Nov 3. Chem Sci. 2021. PMID: 34760216 Free PMC article.
-
Identification of Potential p38γ Inhibitors via In Silico Screening, In Vitro Bioassay and Molecular Dynamics Simulation Studies.Int J Mol Sci. 2023 Apr 17;24(8):7360. doi: 10.3390/ijms24087360. Int J Mol Sci. 2023. PMID: 37108523 Free PMC article.
-
Quantum chemical predictions of water-octanol partition coefficients applied to the SAMPL6 logP blind challenge.J Comput Aided Mol Des. 2020 May;34(5):485-493. doi: 10.1007/s10822-020-00286-1. Epub 2020 Jan 30. J Comput Aided Mol Des. 2020. PMID: 32002778 Free PMC article.
-
Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.Front Immunol. 2024 Aug 14;15:1438030. doi: 10.3389/fimmu.2024.1438030. eCollection 2024. Front Immunol. 2024. PMID: 39206192 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources